@article{4466,
  keywords = {Humans, Hypersensitivity, Delayed, Immunotherapy, Interleukin-2, Neoplasms, Receptors, Interleukin-2, Signal Transduction},
  author = {Kaplan G and Cohn Z A and Smith K A},
  title = {Rational immunotherapy with interleukin 2.},
  abstract = {<p>Interleukin 2 (IL-2), a T lymphocyte product released upon antigen stimulation, has been used for cancer therapy in high doses for more than five years. More recently, its potential as a stimulant of cell-mediated immunity in infectious diseases, particularly those caused by intracellular microbes, has become appreciated. Drawing on the extensive information available as to the structure, cellular and molecular effects of IL-2, this review focuses on its use in patients with lepromatous leprosy and AIDS in low, physiologic doses. The data indicate that IL-2 is effective in stimulating cell-mediated immunity without systemic toxicity.</p>},
  year = {1992},
  journal = {Bio/technology (Nature Publishing Company)},
  volume = {10},
  pages = {157-62},
  month = {1992 Feb},
  issn = {0733-222X},
  language = {eng},
}